Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

This study, called COSTCOM, is looking at how financial counseling and support can help cancer patients. Many people with cancer face financial challenges that can make it hard to stick with their treatment. This study compares standard care with a program called CostCOM, which offers financial counseling, education, and resources. The goal is to see if CostCOM can help patients stay on track with their cancer care and reduce their financial stress. The study plans to enroll 760 participants with solid tumor cancers. Success will be measured by whether patients are better able to follow their cancer care plan after 12 months.

Study design: This is an interventional study comparing enhanced usual care with the CostCOM financial counseling program. It plans to enroll 760 participants.
What's involved: Participants may receive a brochure, financial counseling, and participate in a one-on-one interview or surveys.
Compensation: Not stated in the trial record.
Follow-up: Participants will be followed for 12 months after completing a baseline survey to assess various outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

Active, Not Recruiting

NAAll AgesInterventionalHealth services

ECOG-ACRIN Cancer Research Group

~760 participants

Updated 2026-09-04 on ClinicalTrials.gov

What's tested:Best PracticeFinancial NavigationInterviewSurvey Administration

At a glance

Recruiting sites

0 of 391 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Cost-related cancer care non-adherence

Measured over 12 months

Conditions

Malignant Solid Neoplasm

NCT06295367

Where you'd take part

This study runs at 391 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Abbott-Northwestern Hospital
Minneapolis, Minnesotano site contact published
Adena Regional Medical Center
Chillicothe, Ohiono site contact published
AdventHealth Hendersonville
Hendersonville, North Carolinano site contact published
AdventHealth Infusion Center Asheville
Asheville, North Carolinano site contact published
AdventHealth Infusion Center Haywood
Clyde, North Carolinano site contact published
AdventHealth Infusion Center Weaverville
Weaverville, North Carolinano site contact published
Alaska Breast Care and Surgery LLC
Anchorage, Alaskano site contact published
Alaska Oncology and Hematology LLC
Anchorage, Alaskano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Gelareh Sadigh · PRINCIPAL_INVESTIGATOR · ECOG-ACRIN Cancer Research Group

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

NON-PATIENTS PARTICIPANTS: Participant must speak English

NON-PATIENTS PARTICIPANTS: Participant must be employed at National Cancer Institute Community Oncology Research Program (NCORP) site for at least six months

NON-PATIENTS PARTICIPANTS: Participant must be able to provide informed consent to participate in this study

NON-PATIENTS PARTICIPANTS: Participant must be one of the following:

A study coordinator with a role involving use of CostCOM intervention price transparency and financial navigation platform

A practice oncology provider (i.e., physician or mid-level), or

A practice financial counselor, social workers, financial navigators, or pharmacist who have provided care or been in contact (in the last 3 months) to a patient who was assigned to the CostCOM arm, and who completed the at least 6 month study follow-up

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must be ≥ 18 years of age

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must be fluent in written and spoken English OR patient must be fluent in written and spoken Spanish

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must be within 120 days of a new diagnosis of any solid cancer of any stage at the time of Step 0

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must have had their first medical oncology visit at the time of Step 0

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must have initiated oral or intravenous (IV) cancer systemic therapy or have received a prescription order with stated intent to initiate within 30 days following Step 0 consent

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patients must not have indolent cancer undergoing observation alone (i.e., active surveillance)

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patients must not be receiving palliative or hospice care alone

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be undergoing curative surgery alone or radiation therapy alone. (Must be receiving systemic therapy), unless they are receiving systemic therapy

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must confirm that they intend to receive their care or monitoring at one of the participating NCORP practices

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must have the ability to understand and the willingness to sign a written informed consent document.

Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available are not eligible

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not have an Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3, OR

Patient must not be deemed medically unable to participate in the study by the study investigators or an oncology clinician (i.e., referral to hospice)

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be enrolled in treatment clinical trials where cancer systemic therapy is provided at no cost to the patient

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be enrolled in EAQ221CD or S1912CD given financial navigation is offered as part of these two trials.

NOTE: If S1912CD is activated in a participating practice, S1912CD should be offered first to patients with metastatic cancer meeting eligibility criteria for S1912CD. Only if a patient is not eligible or not interested in participating in S1912CD, the EAQ222CD can be offered. For early stage cancer, EAQ222CD can be offered first given S1912CD does not enroll patients with early stage cancer

PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be enrolled in other clinical trials where OOPC communication or financial navigation (i.e., professional guidance to identify financial assistance programs to alleviate cost of care) is being offered as part of the trial

NOTE: If a trial is offering financial counseling alone without financial navigation patients are allowed to co-enroll

NOTE: Gift cards for survey completion, or parking passes are not considered financial navigation

PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patient must meet all the eligibility criteria for step 0

PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patient must have signed a written informed consent form

PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patient must have a completed baseline survey in ECOG American College of Radiology Imaging Network Systems for Easy Entry of Patient Reported Outcomes (EASEE-PRO) within 30 days of the date of OPEN registration and consent (step 0)

PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patients must have initiated their cancer treatment (i.e., IV or oral systemic therapy) either before or within 30 days of the date of OPEN registration and consent (step 0)

What this trial measures

Cost-related cancer care non-adherence12 months
Cost-related cancer care non-adherence is defined as a positive response to any of the following due to costs: Delayed, forewent, stopped, or changed prescribed cancer medication; or delayed, forewent, or refused recommended cancer tests, or cancer office visits. Will be calculated as a report of non-adherence at any point up through the 12mo follow-up survey.

Trialytics